Lumateperone in Bipolar Depression

Topics: Bipolar Depression | Bipolar Disorder | Bipolar II | Lumateperone | Second Generation Antipsychotics (SGAs)

REVIEW OF: Calabrese JR et al, Am J Psychiatry 2021. Epub ahead of print STUDY TYPE: Randomized, placebo-controlled trial In 2019, lumateperone (Caplyta) became the 13th atypical antipsychotic with FDA approval in schizophrenia. Compared to other atypicals, it is relatively well tolerated, with low rates of akathisia and metabolic side effects. On

A Novel Treatment for Methamphetamine Use Disorder

Topics: Bipolar Depression | Bipolar Disorder | Bipolar II | Lumateperone | Second Generation Antipsychotics (SGAs)

REVIEW OF: Trivedi MH et al, N Engl J Med 2021;384(2):140–153 STUDY TYPE: Randomized, double-blind, placebo-controlled trial with sequential parallel comparison design Methamphetamine use disorder is an increasing cause of overdose deaths in the US. Pharmacologic options are scarce, but pilot studies suggest that bupropion and naltrexone may be

A New Antipsychotic for Bipolar Depression

Topics: Antipsychotics | Bipolar Depression | Bipolar Disorder | Bipolar II | Caplyta | Lumateperone | Research Update

Lumateperone (Caplyta) just hit the pharmacy shelves with FDA approval in schizophrenia (see TCPR March 2020), and its manufacturer is pursuing further approval for bipolar depression. So far they’ve completed two phase III trials—one negative and one positive—and the positive one was presented in poster form by Suresh Durgam and colleagues at the

Lumateperone and lemborexant

Topics: Antipsychotics | Belsomra | Caplyta | Dayvigo | Hypnotics | Lemborexant | Lumateperone | News of Note | Orexin | Pharmacology | Psychopharmacology | Suvorexant

Two new psychiatric medications were approved in the final days of 2019. One is the first of its kind, an antipsychotic with minimal dopaminergic blockade: lumateperone (Caplyta). The other is lemborexant (Dayvigo), a variation on the hypnotic suvorexant (Belsomra). Lumateperone (Caplyta)Though classified as an atypical antipsychotic, lumateperone is u